cmx-2043
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2010 (NCT00984802)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Lipoyl synthase, mitochondrialSupplementation
LIAS supplementation
Chemistry & pharmacology
Loading structure…
SMILES
C[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)CCCC[C@@H]1CCSS1)C(=O)O- Mol. weight
- 406.53 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3099551 ↗
Also known as
- alpha-n-(1,2-dithiolane-3-pentanoyl)glutamylalanine
- alpha-n-(1,2-dithiolane-3-pentanoyl)-l-glutamyl-l-alanine
- cmx-2043
- cmx-2043
- cmx-2043
- cmx-2043
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02103959 | Phase 2 | Jun 1, 2014 | Ischemix, LLC |
| NCT00984802 | Phase 2 | Feb 1, 2010 | Ischemix, LLC |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ischemix, LLC | For profit | 2 | 2 | 1 | 2010 |
1 organizations
Page 1 / 1